Posted by Michael Wonder on 19 Nov 2025
Esperion partner HLS Therapeutics announces approval of Nilemdo for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease
18 November 2025 - Esperion today announced that HLS Therapeutics, the Company’s partner in Canada for the development and commercialization of Nilemdo (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe), has received approval from Health Canada to market Nilemdo for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease.
Commercial launch for Nilemdo is expected in Q2, 2026.
